Research Technician

Why wall street maintains buy stance on AbCellera Biologics Inc. (ABCL) amid business model evolution? Published on November 18, 2025 at 6:17 am by abdul rahman in news. AbCellera Biologics Inc. (NASDAQ:ABCL) is a must-buy penny stock to buy now. On November 13, at the Stifel 2025 Healthcare Conference, AbCellera Biologics Inc. (NASDAQ:ABCL) reaffirmed its strategic evolution into a company focused on developing clinical assets. The company will no longer operate under a partnership model but will develop its own assets backed by a strong financial position. With over $500 million in cash and equivalents, AbCellera is focused on the development of ABCL635, a first-in-class antibody medicine for the non-hormonal treatment of moderate to severe menopausal hot flashes. The company is also working on ABCL575, an antibody for the treatment of moderate-to-severe atopic dermatitis (AD). Even as the company continues to work on its clinical assets, strategic partnerships with big Pharma, including Eli Lilly and AbbVie, are crucial. The internal clinical assets are only seen as a presale activity for future licensing. Amid the new strategic focus, on November 7, TD Cowen analyst Brendan Smith reiterated a Buy rating, as Stifel Nicolaus analyst Stephen Wiley echoed similar sentiments with a Buy rating and a $7 price target. AbCellera Biologics Inc. (NASDAQ:ABCL) is a clinical-stage biotechnology company that discovers and develops antibody-based medicines for a range of diseases, including cancer, metabolic and endocrine conditions, and autoimmune disorders. While we acknowledge the potential of AbCellera Biologics Inc. (NASDAQ:ABCL) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABCL and that has 100x upside potential, check out our report about the cheapest AI stock. Disclosure: None. This article is originally published at Insider Monkey.

AbCellera appoints Dr. Stephen Quake to its Board of Directors. VANCOUVER, British Columbia-(BUSINESS WIRE)-AbCellera (Nasdaq: ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director. Dr. Quake is a distinguished scientist, inventor, and entrepreneur who has made foundational contributions across diverse fields, including single molecule biophysics, microfluidics, single cell analysis, genomics, molecular diagnostics, and non-invasive prenatal testing. His work is represented in over 300 publications (h-index of 181) and 80+ patents and patent applications. "We are pleased to welcome Dr. Quake to AbCellera's Board of Directors. His presence reinforces our commitment to excellence in science and technology," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "He brings a distinctive combination of scientific breadth, creativity, and interdisciplinarity that resonates with AbCellera's culture and strategy." Dr. Quake is currently the Lee Otterson Professor of Bioengineering and Professor of Applied Physics at Stanford University and was previously the Thomas and Doris Everhart Professor of Applied Physics and Physics at Caltech. He has been elected to four U.S. national academies: the National Academies of Sciences, Engineering, Medicine, and Inventors. In 2025, Dr. Quake was elected as a Foreign Member of the Royal Society. Dr. Quake was the founding co-president of the Chan Zuckerberg Biohub starting in 2016 and later became president of the Chan Zuckerberg Biohub Network and Head of Science for the Chan Zuckerberg Initiative until 2025. Under his leadership, the Biohub had a launch budget of approximately $600 million and delivered on foundational large-scale science programs, including several whole organism Single Cell Atlases. As an entrepreneur, Dr. Quake has cofounded more than a dozen companies developing products in fields of microfluidics, genomics, molecular diagnostics, and therapeutics. "I greatly admire what Carl and the AbCellera team have accomplished to date, and I'm thrilled to join the team and be a part of it going forward," said Dr. Quake. Dr. Quake received a B.S. in Physics and M.S. in Mathematics from Stanford University and a doctorate in Theoretical Physics from the University of Oxford. Concurrent with Dr. Quake's appointment, Andrew W. Lo, Ph.D., will be resigning as independent director. Dr. Lo, a cofounder of BridgeBio Pharma and the Charles E. and Susan T. Harris Professor of Finance at the MIT Sloan School of Management, joined the Board in December 2021 and served on Audit and Nominating and Corporate Governance Committees. "It has been a pleasure to work with Andrew over the past four years. His guidance and unique financial insights have meaningfully contributed to advancing AbCellera's business and strategy," said Dr. Hansen. "Our team and board thank Andrew for his leadership and wish him the best in his future endeavors." AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit www.abcellera.com. Inquiries Media: Tiffany Chiu; [email protected], +1(236)521-6774 Partnering: Murray McCutcheon, Ph.D.; [email protected], +1(604)559-9005 Investor Relations: Peter Ahn; [email protected], +1(778)729-9116 Source: AbCellera Biologics Inc. VANCOUVER, British Columbia-( BUSINESS WIRE )-AbCellera Reports Q3 2025 Business Results... VANCOUVER, British Columbia-( BUSINESS WIRE )-AbCellera to Participate at Upcoming Investor Conferences in November and December 2025... VANCOUVER, British Columbia-( BUSINESS WIRE )-AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025...

AbCellera appoints Dr. Sarah Noonberg as Chief Medical Officer.